# D-0120 Safety and PK/PD Study in China

> **NCT03923868** · PHASE1,PHASE2 · COMPLETED · sponsor: **InventisBio Co., Ltd** · enrollment: 52 (actual)

## Conditions studied

- Hyperuricemia or Gout

## Interventions

- **DRUG:** D-0120

## Key facts

- **NCT ID:** NCT03923868
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-18
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03923868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03923868, "D-0120 Safety and PK/PD Study in China". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03923868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*